Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Ordinary Shares, no par value
-
Shares outstanding
-
156M
-
Number of holders
-
79
-
Total 13F shares, excl. options
-
72.1M
-
Shares change
-
+2.11M
-
Total reported value, excl. options
-
$263M
-
Value change
-
+$6.6M
-
Put/Call ratio
-
0.49
-
Number of buys
-
45
-
Number of sells
-
-35
-
Price
-
$3.64
Significant Holders of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) as of Q2 2023
99 filings reported holding WVE - Wave Life Sciences Ltd. - Ordinary Shares, no par value as of Q2 2023.
Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) has 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 72.1M shares
of 156M outstanding shares and own 46.36% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (17.2M shares), M28 Capital Management LP (7.05M shares), MAVERICK CAPITAL LTD (6.6M shares), 683 Capital Management, LLC (6.03M shares), BlackRock Inc. (4.62M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (4.62M shares), Bellevue Group AG (4.49M shares), Kynam Capital Management, LP (3.92M shares), PRIMECAP MANAGEMENT CO/CA/ (3.81M shares), and Artal Group S.A. (2.87M shares).
This table shows the top 79 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.